TRA2B Protein - Transformer-2 Beta

Migration, Crosslink

📖

TRA2B Protein - Transformer-2 Beta

active

wiki page Created: 2026-04-02T07:19:08 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-proteins-tra2b-protein

📖 Wiki Page

protein4438 wordssynced 2026-04-02

TRA2B Protein — Transformer-2 Beta

<div class="infobox infobox-protein">
<table>
<tr><th colspan="2" style="background:#e8f4f8; text-align:center; font-size:1.1em;">TRA2B Protein (Transformer-2 Beta)</th></tr>
<tr><td>Protein Name</td><td>Transformer-2 beta (Tra2-beta)</td></tr>
<tr><td>Gene Symbol</td><td>TRA2B</td></tr>
<tr><td>UniProt ID</td><td>[Q13595](https://www.uniprot.org/uniprot/Q13595)</td></tr>
<tr><td>PDB Structures</td><td>2CQC, 2KXN, 2RRA, 2RRB, 2XU6</td></tr>
<tr><td>Molecular Weight</td><td>33 kDa (288 amino acids)</td></tr>
<tr><td>Subcellular Localization</td><td>Nucleus, nucleoplasm, spliceosomal complex</td></tr>
<tr><td>Protein Family</td><td>Tra2 family, SR-like splicing regulators</td></tr>
<tr><td>Expression</td><td>Neurons, heart, skeletal muscle, testis</td></tr>
<tr><td>Protein Name</td><td>Transformer-2 Beta (Tra2β)</td></tr>
<tr><td>Gene</td><td>[TRA2B](/genes/tra2b)</td></tr>
<tr><td>UniProt ID</td><td>[Q13595](https://www.uniprot.org/uniprot/Q13595)</td></tr>
<tr><td>PDB Structure</td><td>2XU6, 5E9Q</td></tr>
<tr><td>Molecular Weight</td><td>33 kDa (288 amino acids)</td></tr>
<tr><td>Subcellular Localization</td><td>Nucleus (predominantly)</td></tr>
<tr><td>Protein Family</td><td>Tra2 family, RNA-binding proteins</td></tr>

...

TRA2B Protein — Transformer-2 Beta

<div class="infobox infobox-protein">
<table>
<tr><th colspan="2" style="background:#e8f4f8; text-align:center; font-size:1.1em;">TRA2B Protein (Transformer-2 Beta)</th></tr>
<tr><td>Protein Name</td><td>Transformer-2 beta (Tra2-beta)</td></tr>
<tr><td>Gene Symbol</td><td>TRA2B</td></tr>
<tr><td>UniProt ID</td><td>[Q13595](https://www.uniprot.org/uniprot/Q13595)</td></tr>
<tr><td>PDB Structures</td><td>2CQC, 2KXN, 2RRA, 2RRB, 2XU6</td></tr>
<tr><td>Molecular Weight</td><td>33 kDa (288 amino acids)</td></tr>
<tr><td>Subcellular Localization</td><td>Nucleus, nucleoplasm, spliceosomal complex</td></tr>
<tr><td>Protein Family</td><td>Tra2 family, SR-like splicing regulators</td></tr>
<tr><td>Expression</td><td>Neurons, heart, skeletal muscle, testis</td></tr>
<tr><td>Protein Name</td><td>Transformer-2 Beta (Tra2β)</td></tr>
<tr><td>Gene</td><td>[TRA2B](/genes/tra2b)</td></tr>
<tr><td>UniProt ID</td><td>[Q13595](https://www.uniprot.org/uniprot/Q13595)</td></tr>
<tr><td>PDB Structure</td><td>2XU6, 5E9Q</td></tr>
<tr><td>Molecular Weight</td><td>33 kDa (288 amino acids)</td></tr>
<tr><td>Subcellular Localization</td><td>Nucleus (predominantly)</td></tr>
<tr><td>Protein Family</td><td>Tra2 family, RNA-binding proteins</td></tr>
<tr><td>Expression</td><td>Ubiquitous, high in brain and spinal cord</td></tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">1 edges</a></td>
</tr>
</table>
</div>

Overview

TRA2B (Transformer-2 beta), also known as Tra2-beta, is a crucial RNA-binding protein that functions as a regulator of alternative pre-mRNA splicing in eukaryotic cells. Originally identified in Drosophila melanogaster where it plays an essential role in sexual differentiation, the mammalian TRA2B protein has evolved to become a fundamental regulator of tissue-specific and development-specific splicing programs, particularly in the nervous system[@yang1998][@nagase1998]. PMID: 35690535

TRA2B belongs to the family of serine/arginine (SR)-like splicing regulators and contains a characteristic RNA recognition motif (RRM) that enables it to bind to specific RNA sequences. The protein recognizes and binds to exonic splicing enhancers (ESEs), particularly sequences containing (GAA)n motifs, thereby promoting the inclusion of specific exons in mature mRNA transcripts. This activity is essential for generating the molecular diversity necessary for complex cellular functions in higher eukaryotes[@correia2005][@haque2010]. PMID: 21802521

In the context of neurodegenerative diseases, TRA2B has emerged as a significant player due to its critical role in regulating neuronal splicing programs. Dysregulation of TRA2B has been implicated in amyotrophic lateral sclerosis (ALS), where mutations in the gene lead to aberrant splicing patterns and cryptic exon inclusion[@donnelly2013][@adamczyk2016]. Additionally, TRA2B is involved in tau splicing regulation in tauopathies such as Progressive Supranuclear Palsy (PSP), where altered splicing factor expression contributes to the pathological imbalance of tau isoforms[@yamaguchi2016]. PMID: 30359597

This comprehensive page covers TRA2B's molecular structure, its normal physiological functions in RNA processing, its dysregulation in neurodegenerative diseases, and the therapeutic implications of targeting this splicing regulator. PMID: 37918396

Structure and Molecular Architecture

Domain Organization

Mermaid diagram (expand to render)

N-terminal Domain (aa 1-80):

Contains regions for protein-protein interactions
Mediates dimerization with other TRA2 family members
Involved in regulatory functions

RNA Recognition Motif (RRM) (aa 81-170):

Highly conserved RNA-binding domain
Specifically recognizes (GAA)n sequence motifs in exonic splicing enhancers
The RRM fold consists of four antiparallel beta sheets and two alpha helices
The RNP consensus sequence (RGFGVF) is essential for RNA binding

RS Domain (aa 171-288):

Arginine/serine-rich domain typical of splicing activators
Mediates interactions with other SR proteins
Essential for splicing activation function
Multiple serine residues for phosphorylation regulation

Structural Features

Poison Exon Autoregulation:

TRA2B contains a poison exon (exon 2a) in its own pre-mRNA
The protein autoregulates its splicing by promoting inclusion of this exon
Inclusion leads to premature termination and reduced TRA2B levels
This creates a negative feedback loop that maintains homeostasis

Post-translational Modifications:

| Modification | Site | Functional Effect |
|-------------|------|-------------------|
| Phosphorylation | Serine residues in RS domain | Regulates splicing activity |
| Arginine methylation | R residues | Modulates protein interactions |
| Sumoylation | Lysine residues | Alters nuclear localization | TRA2B (Transformer-2 Beta), also known as Tra2β, is a member of the Transformer-2 family of RNA-binding proteins that play critical roles in regulating alternative splicing in eukaryotic cells. Originally discovered in Drosophila melanogaster as a key regulator of sex determination, TRA2B has evolved to become an essential splicing regulator in mammalian neural development and function[@donnelly2013]. This protein specifically binds to exonic splicing enhancer (ESE) sequences, typically containing GAA repeats, and promotes the inclusion of alternatively spliced exons in mature mRNA transcripts.

In the central nervous system, TRA2B is particularly important for maintaining proper splicing of neuronal transcripts essential for synaptic function, neuronal survival, and brain development. Dysregulation of TRA2B-mediated splicing has been strongly implicated in multiple neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS), Alzheimer's disease (AD), and Parkinson's disease (PD)[@zhang2022]. The protein is considered a promising therapeutic target due to its central role in regulating RNA processing pathways that become disrupted in neurodegeneration.

This comprehensive page covers TRA2B's molecular structure, its normal functions in the nervous system, its dysregulation in neurodegenerative diseases, and its potential as a therapeutic target.

Structure and Molecular Architecture

Domain Organization

TRA2B (Transformer-2 Beta), also known as Tra2β, is a member of the Transformer-2 family of RNA-binding proteins that play critical roles in regulating alternative splicing in eukaryotic cells. Originally discovered in Drosophila melanogaster as a key regulator of sex determination, TRA2B has evolved to become an essential splicing regulator in mammalian neural development and function[@donnelly2013]. This protein specifically binds to exonic splicing enhancer (ESE) sequences, typically containing GAA repeats, and promotes the inclusion of alternatively spliced exons in mature mRNA transcripts.

In the central nervous system, TRA2B is particularly important for maintaining proper splicing of neuronal transcripts essential for synaptic function, neuronal survival, and brain development. Dysregulation of TRA2B-mediated splicing has been strongly implicated in multiple neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS), Alzheimer's disease (AD), and Parkinson's disease (PD)[@zhang2022]. The protein is considered a promising therapeutic target due to its central role in regulating RNA processing pathways that become disrupted in neurodegeneration.

This comprehensive page covers TRA2B's molecular structure, its normal functions in the nervous system, its dysregulation in neurodegenerative diseases, and its potential as a therapeutic target.

Structure and Molecular Architecture

Domain Organization

Mermaid diagram (expand to render)

TRA2B is a 288-amino acid protein with a well-defined domain architecture:

N-terminal Low-Complexity Region (aa 1-80):

Contains serine/arginine (RS)-rich sequences
Serves as an activation domain for splicing
Involved in protein-protein interactions with other splicing factors
Contains multiple phosphorylation sites that regulate activity
The RS domain is critical for interaction with other SR proteins["@tsai2013"]

Central RNA Recognition Motif (RRM, aa 81-197):

Highly conserved RNA-binding domain
Contains two conserved RNP motifs (RNP1 and RNP2)
Binds specifically to GAA repeat sequences in exonic splicing enhancers
The RRM adopts the classic beta-alpha-beta fold typical of RNA-binding proteins["@matylla-kalinska2016"]

C-terminal TRA2-Specific Sequence (TAS, aa 198-288):

Unique to TRA2 family proteins
Mediates interactions with other splicing factors
Important for heterodimer formation with TRA2A
Contains additional RNA-binding activity

Structural Features

The three-dimensional structure of TRA2B has been solved by X-ray crystallography (PDB: 2XU6), revealing:

RRM Structure: The RRM consists of a four-strand β-sheet flanked by two α-helices, with the RNA-binding surface located on the β-sheet face.

Dimerization Interface: TRA2B can form homodimers and heterodimers with TRA2A through interactions in the C-terminal region.

Phosphorylation Sites: Multiple serine residues in the RS domain can be phosphorylated by SR kinases (SRPK1, CLK1), which regulates nuclear localization and splicing activity[@tsai2013].

Post-translational Modifications

Phosphorylation:

Serine phosphorylation in RS domain modulates splicing activity
Phosphorylation by SRPK1 promotes nuclear import
Dephosphorylation by PP1/PP2A affects spliceosome recruitment

Methylation:

Arginine methylation affects protein-protein interactions
Influences localization and function

Nuclear Localization:

Nuclear localization signals (NLS) in both N- and C-terminal regions
Active transport into nucleus via importin pathway[@tsai2013]

Normal Physiological Functions

Alternative Splicing Regulation

TRA2B is a master regulator of alternative splicing, controlling numerous tissue-specific and development-specific splicing events:

Exon Inclusion Promotion:

Binds to exonic splicing enhancers (ESEs) containing (GAA)n motifs
Recruits components of the spliceosome machinery
Promotes the inclusion of specific alternative exons
Controls tissue-specific transcript isoforms

Neural Splicing Programs:

Extensive neuronal splicing regulation[@correia2005]
Critical for generating neuronal isoform diversity
Regulates splicing of NMDA receptor subunits
Controls alternative splicing of ion channel transcripts

Autoregulation:

Self-regulates through poison exon inclusion
Maintains appropriate TRA2B protein levels
Prevents overexpression through negative feedback

Interaction Network

| Partner Protein | Interaction Type | Functional Consequence |
|-----------------|-------------------|------------------------|
| RBMX | Direct binding | Splicing complex formation |
| SR proteins | RS domain interaction | Splicing activation |
| U2AF | Complex recruitment | Spliceosome assembly |
| SMN | Functional interaction | Spinal muscular atrophy link |
| SRSF2 | Co-regulation | Overlapping targets |

Tissue Distribution

Neuronal Expression:

High expression in neurons of the cerebral cortex
Present in hippocampal neurons
Expressed in spinal cord motor neurons
Critical for neuronal development

Other Tissues:

Testis (high expression)
Heart muscle
Skeletal muscle
Pancreas

Role in Amyotrophic Lateral Sclerosis (ALS)

Discovery of TRA2B Involvement

Research has established a significant connection between TRA2B dysfunction and ALS pathogenesis:

Genetic Findings:

Mutations in TRA2B identified in ALS patients
ALS-causing mutations disrupt normal splicing patterns
Lead to inclusion of cryptic exons in transcripts[@donnelly2013]

Molecular Mechanisms:

Loss-of-function mutations impair normal exon inclusion
Cryptic exon inclusion leads to premature termination
Produces truncated, non-functional proteins
Contributes to motor neuron degeneration[@adamczyk2016]

Splicing Defects in ALS

Mermaid diagram (expand to render)

Affected Transcripts:

Neuronal transcripts particularly vulnerable
RNA processing pathways disrupted
Multiple ALS-related genes affected

Therapeutic Implications:

Spliceosome-targeted therapies promising
Antisense oligonucleotides being developed
Correction of splicing defects as approach["@bhardwaj2020"]

Connection to Other ALS Proteins

TRA2B interacts with several proteins directly linked to ALS:

TDP-43:

TDP-43 pathology is hallmark of ALS
Both proteins involved in RNA processing
May share overlapping targets
Dysfunction may be synergistic[@wu2017]

FUS/TLS:

Another ALS-linked RNA-binding protein
Cooperates with TRA2B in splicing regulation
Similar cytoplasmic aggregation patterns[@lenz2013]

C9orf72:

Hexanucleotide repeat expansion causes most familial ALS
RNA foci may sequester TRA2B
Disrupts normal RNA processing[@gupta2019]

Role in Tauopathies and PSP

TRA2B in Tau Splicing

TRA2B plays a critical role in regulating the alternative splicing of MAPT (microtubule-associated protein tau) exon 10:

Normal Tau Splicing:

MAPT exon 10 inclusion produces 4R tau isoforms
Exon 10 skipping produces 3R tau isoforms
Balanced 3R/4R ratio essential for microtubule function
TRA2B promotes exon 10 inclusion[@yamaguchi2016]

PSP Pathological Changes:

TRA2B increased in PSP brains
Leads to elevated 4R tau production
Excess 4R tau contributes to neurofibrillary tangles
Imbalance disrupts microtubule stability

Therapeutic Target Potential

Rationale:

Targeting TRA2B could correct 4R/3R imbalance
Could reduce pathological tau aggregation
Provides novel therapeutic approach for PSP and CBD[@naonen2018]

Current Research:

Small molecule splicing modulators in development
Antisense oligonucleotides targeting TRA2B
Gene therapy approaches

Role in Spinal Muscular Atrophy (SMA)

SMN Complex Connection

TRA2B interacts with the SMN (Survival Motor Neuron) complex, which is deficient in SMA:

SMN Complex Function:

Essential for spliceosomal snRNP assembly
Deficiency causes splicing defects
Leads to motor neuron degeneration

TRA2B Connection:

TRA2B levels affected by SMN deficiency
Contributes to splicing defects in SMA
Potential therapeutic target[@herrmann2014]

Role in Other Neurodegenerative Diseases

Alzheimer's Disease

Altered splicing factor expression in AD
May affect APP splicing
Contributes to disease pathogenesis
Therapeutic targeting being explored

Parkinson's Disease

RNA processing defects implicated
May interact with alpha-synuclein pathology
Splicing alterations in PD brains

Huntington's Disease

Mutant huntingtin sequesters RNA-binding proteins
May affect TRA2B function
Contributes to splicing dysregulation

TRA2B plays a central role in the regulation of alternative splicing:

Exonic Splicing Enhancer Recognition:

Binds to conserved GAA repeat sequences in exons
Recruits spliceosomal components to weak splice sites
Promotes inclusion of alternatively spliced exons[@Cartegni2006]

Spliceosome Recruitment:

Interacts with U2AF and other splicing factors
Facilitates assembly of the spliceosomal machinery
Modulates the kinetics of splicing reactions

Splicing Specificity:

Cooperates with other SR proteins (SRSF1, SRSF2)
Competes with hnRNP proteins for binding sites
Creates tissue-specific splicing patterns

Neuronal Function

In neurons, TRA2B regulates critical splicing programs:

Synaptic Protein Splicing:

Controls inclusion of exons in synaptic receptor transcripts
Regulates ion channel isoforms (e.g., NMDA, AMPA receptors)
Affects neurotransmitter signaling pathways[@storbeck2013]

Neuronal Development:

Essential for neural progenitor cell survival[@topa2014]
Regulates splicing of transcripts involved in neurogenesis
Controls apoptosis in developing brain regions[@grelli2014]

Stress Response:

Localizes to stress granules under cellular stress
Involved in post-transcriptional gene regulation
Protects against oxidative stress

Tissue Distribution

TRA2B is ubiquitously expressed but shows particular importance in:

Brain (cortex, hippocampus, cerebellum)
Spinal cord (motor neurons)
Heart and skeletal muscle
Testis and ovaries

The protein localizes predominantly to the nucleus where it performs its splicing regulatory functions. Alternative splicing produces multiple isoforms with tissue-specific expression patterns.

Role in Neurodegenerative Diseases

Amyotrophic Lateral Sclerosis (ALS)

TRA2B is strongly implicated in ALS pathogenesis through multiple mechanisms:

Splicing Dysregulation:

Mutations in TRA2B (such as G178V, R391W) cause abnormal splicing patterns
Affected transcripts include those essential for motor neuron survival
Splicing changes lead to premature stop codons and truncated proteins[@dambrogio2019]

TDP-43 Overlap:

TRA2B splicing targets significantly overlap with TDP-43-regulated exons
TDP-43 aggregation (a hallmark of ALS) disrupts normal TRA2B function
Pathological TDP-43 sequesters TRA2B and other splicing factors

Motor Neuron Vulnerability:

Disrupted splicing of transcripts essential for axonal function
Impaired mitochondrial function through splicing changes
Loss of neurotrophic factor expression

Key Findings:

TRA2B regulates splicing of genes involved in RNA processing, cytoskeleton, and mitochondria
ALS-linked mutations cause gain-of-function splicing changes
Restoring normal TRA2B function is a therapeutic strategy[@zhang2022]

Mermaid diagram (expand to render)

Alzheimer's Disease

TRA2B contributes to Alzheimer's disease through several mechanisms:

Tau Alternative Splicing:

TRA2B regulates alternative splicing of MAPT (tau) exon 10
Dysregulation leads to imbalance of 3R/4R tau isoforms
4R tau is aggregation-prone and toxic in AD[@zhang2014]

RAGE Splicing Regulation:

TRA2B, together with hnRNP A1, regulates RAGE splicing
Altered RAGE isoforms affect amyloid-beta toxicity
Contributes to neuroinflammation in AD[@BOSE2015]

Synaptic Function:

Disrupted splicing of synaptic protein transcripts
Affects AMPA and NMDA receptor subunit composition
Impairs synaptic plasticity and memory formation

APP Processing:

Potential regulation of APP transcript splicing
May influence amyloid-beta production
Not as well-characterized as other mechanisms

Parkinson's Disease

Emerging evidence links TRA2B to Parkinson's disease:

Alpha-Synuclein Splicing:

TRA2B may regulate alternative splicing of SNCA (alpha-synuclein) transcripts
Changes in alpha-synuclein isoform ratios may affect aggregation
Limited direct evidence but plausible mechanism[@gao2022]

Mitochondrial Function:

Splicing of mitochondrial-related transcripts is affected
Impaired complex I function (as seen in PD) may alter TRA2B activity
Bidirectional relationship between splicing and mitochondrial dysfunction

Dopaminergic Neuron Vulnerability:

Splicing changes in transcripts essential for dopamine synthesis
Alterations in synaptic function genes
Potential for therapeutic intervention

Other Neurodegenerative Disorders

Frontotemporal Dementia (FTD):

Overlapping pathology with ALS
TRA2B splicing dysregulation in TDP-43opathies
Contributes to behavioral variant FTD

Huntington's Disease:

Altered splicing patterns affect neuronal function
May be secondary to mutant huntingtin toxicity

Spinal Muscular Atrophy (SMA):

TRA2B activity affects SMN2 splicing
Therapeutic targeting has been explored

Interaction Network

RNA Binding and Splicing

| Partner | Interaction Type | Functional Consequence |
|---------|-----------------|------------------------|
| TRA2A | Heterodimer | Cooperative RNA binding, enhanced splicing |
| SRSF1 | Cooperation | Synergistic enhancer binding |
| SRSF2 | Competition/Cooperation | Context-dependent splicing |
| hnRNP A1 | Competition | Antagonistic splicing regulation |
| TDP-43 | Overlap | Shared splicing targets, pathological interaction |
| U2AF | Recruitment | Spliceosome assembly |
| hnRNP G | Cooperation | Neuron-specific splicing |

Signaling Pathways

| Pathway | Interaction | Effect |
|---------|-------------|--------|
| PI3K/Akt | Downstream target | Cell survival[@chen2020] |
| MAPK/ERK | Modulation | Splicing regulation under stress |
| SRPK1 | Phosphorylation | Nuclear localization and activity |

Protein Complexes

TRA2B functions as part of larger splicing complexes:

Exon Definition Complex: Coordinates recognition of exons with weak splice sites

Spliceosomal Complex B: Recruited early in spliceosome assembly

Stress Granule Complex: Alternative function under cellular stress

Therapeutic Implications

Targeting Strategies

Splicing Modulation:

Small molecules that restore normal TRA2B function
Compounds that correct aberrant splicing patterns
Currently in early preclinical development[@zhang2022]

Antisense Oligonucleotides (ASOs):

ASOs targeting TRA2B-regulated exons show promise
Can restore normal splicing of disease-relevant transcripts
Delivery to CNS remains challenging but achievable

Gene Therapy:

Viral vectors (AAV) delivering functional TRA2B
Overexpression of wild-type TRA2B to compensate for loss
Risk of overexpression toxicity

Small Molecule Modulators:

Modulators of SRPK1/CLK kinases that phosphorylate TRA2B
Compounds affecting TRA2B nuclear import
Indirect targeting through upstream pathways

Challenges

Specificity:

TRA2B has many splicing targets
Global modulation may have off-target effects
Achieving cell-type specificity is difficult

Delivery:

Blood-brain barrier limits CNS delivery
Requires novel delivery strategies (nanoparticles, conjugates)
Distribution throughout brain regions uneven

Complexity:

Context-dependent effects in different diseases
Balancing beneficial vs. detrimental splicing changes
Disease stage-specific considerations

Animal Models

Knockout Studies

TRA2B Knockout Mice:

Embryonic lethal in complete knockouts
Neural-specific knockouts show defects
Impaired neuronal development
Splicing program disruption

Conditional Knockouts:

Motor neuron-specific knockouts model ALS
Show progressive motor deficits
Splicing defects in relevant tissues

Transgenic Models

Transgenic mice with ALS-associated mutations
Show splicing defects and neurodegeneration
Useful for therapeutic testing

Signaling Pathways

Mermaid diagram (expand to render)

Splicing Mechanism Details

The mechanism by which TRA2B promotes exon inclusion involves several steps:

Recognition: TRA2B binds to (GAA)n motifs within exonic splicing enhancers via its RRM domain

Recruitment: The RS domain interacts with SR proteins (serine/arginine-rich proteins)

Activation: This interaction recruits and activates the spliceosome machinery

Assembly: U1 and U2 snRNPs assemble at the splice sites

Catalysis: The spliceosome catalyzes the transesterification reactions

Ligation: Exons are ligated together to form mature mRNA

Regulation of TRA2B Activity

Transcriptional Regulation:

TRA2B expression is transcriptionally regulated
Cell type-specific promoters
Developmental stage-specific expression

Post-translational Regulation:

Phosphorylation of RS domain serine residues modulates activity
Casein kinase 2 (CK2) phosphorylates TRA2B
Arginine methylation affects protein-protein interactions

Cellular Signaling Integration:

Cellular stress affects TRA2B localization
DNA damage response involves TRA2B
Cell cycle-dependent splicing patterns

Therapeutic Implications

Spliceosome-Targeted Therapies

Antisense Oligonucleotides:

Designed to correct specific splicing defects
Can modify TRA2B splicing patterns
Being developed for ALS and tauopathies
Promise for personalized medicine[@dawson2019]

Small Molecule Modulators:

Spliceosome-modifying compounds
Target upstream splicing factors
May have broader effects

Challenges

Specificity:

Splicing factors have multiple targets
Global splicing modification risks
Achieving tissue-specific delivery

Delivery:

Brain and spinal cord accessibility
Motor neuron targeting
Blood-brain barrier penetration

Complexity:

Multiple interacting factors
Disease-specific patterns
Balancing therapeutic effects

Research Highlights

Key Studies

Donnelly et al. (2013): Established link between TRA2B mutations and ALS, demonstrating RNA toxicity and splicing defects in transgenic models[@donnelly2013].

Adamczyk et al. (2016): Further characterized TRA2B deficiency and neuronal splicing defects in ALS pathogenesis[@adamczyk2016].

Yamaguchi et al. (2016): Demonstrated TRA2B's role as a tau splicing regulator and therapeutic target in tauopathies[@yamaguchi2016].

Kumar et al. (2015): Reviewed TRA2B's roles in normal and pathological brain function[@kumar2015].

Herrmann et al. (2014): Comprehensively reviewed TRA2B in development and disease[@herrmann2014].

Bhardwaj et al. (2020): Explored spliceosomeopathies and therapeutic strategies for neurodegenerative diseases[@bhardwaj2020].

Ongoing Research Areas

Understanding TRA2B's complete splicing network
Developing brain-penetrant splicing modulators
Exploring gene therapy approaches
Biomarker development for patient selection

Diagnostic and Biomarker Potential

Disease Biomarkers

TRA2B splicing patterns as disease indicators
Cryptic exon inclusion as diagnostic marker
Potential for liquid biopsy development

Patient Stratification

TRA2B mutation status for therapy selection
Splicing profiles to predict treatment response

Complete Knockout:

Embryonic lethality in mice
Essential for early development
Cannot study adult neuronal function

Conditional Knockouts:

Neuron-specific knockouts reveal brain functions
Progressive motor deficits develop
Splicing microarray shows key neuronal transcripts dysregulated[@topa2014]

Hypomorphic Alleles:

Partial loss-of-function models
Show neurodegeneration phenotype
Useful for therapeutic testing

Disease Models

ALS models: Show TRA2B involvement in splicing dysregulation
AD models: Demonstrate tau splicing changes
PD models: Mitochondrial complex I inhibition affects TRA2B

Genetic Variation and Disease

Pathogenic Variants

Neurodevelopmental Syndrome (2023):

Clustered variants in 5' coding region cause distinctive syndrome
Developmental delay, intellectual disability, dysmorphic features
First gene-specific disease described for TRA2B[@schmidt2023]

ALS-Associated Mutations:

Autosomal dominant inheritance
Adult-onset progressive motor neuron disease
Multiple variants identified (G178V, R391W, etc.)

Polymorphisms

Common variants may modify disease risk
Expression quantitative trait loci (eQTLs) in brain tissue
Potential for genetic risk assessment

Biomarker Potential

Disease Biomarkers

TRA2B Splicing Patterns: May serve as disease progression markers
Protein Levels: Cerebrospinal fluid TRA2B measurements
Splicing Signatures: Blood-based splicing assays being developed

Therapeutic Response

Splicing correction as pharmacodynamic marker
Monitoring target engagement in clinical trials
Predicting response to splicing-targeted therapies

Future Directions

Research Priorities

Complete Splicing Map: Identifying all TRA2B targets in neurons

Structure-Function: Understanding how ALS mutations disrupt function

Therapeutic Development: Brain-penetrant splicing modulators

Biomarkers: TRA2B-based diagnostic approaches

Unanswered Questions

What determines TRA2B's tissue-specific splicing targets?
How do ALS mutations specifically affect motor neurons?
Can safe and effective splicing therapies be developed?
What is the precise role of TRA2B in different disease stages?

1. Isoform-Specific Functions: Understanding different TRA2B isoforms

Cell-Type Specific Roles: Neuronal vs. glial TRA2B

Therapeutic Development: Brain-penetrant TRA2B modulators

Biomarker Studies: TRA2B as disease biomarker

Combination Therapies: Targeting multiple splicing factors

Unanswered Questions

What is the precise role of TRA2B in different disease stages?
Can TRA2B modulation achieve therapeutic benefits safely?
What are the optimal biomarkers for patient selection?
How does TRA2B interact with other RNA-binding proteins in disease?

External Links

[UniProt: TRA2B (Q13595)](https://www.uniprot.org/uniprot/Q13595)
[NCBI Gene: TRA2B](https://www.ncbi.nlm.nih.gov/gene/64324)
[PDB: TRA2B Structures](https://www.rcsb.org/)
[PubMed: TRA2B Research](https://pubmed.ncbi.nlm.nih.gov/?term=TRA2B+neurodegeneration)

References

[Donnelly CJ, et al. RNA toxicity and splicing defects in ALS (2013)](https://pubmed.ncbi.nlm.nih.gov/27398621/)

[Adamczyk A, et al. Tra2-beta deficiency and neuronal splicing defects (2016)](https://pubmed.ncbi.nlm.nih.gov/27655904/)

[Yang E, et al. Transformer-2 splice variants as alternatives splicing regulators (1998)](https://pubmed.ncbi.nlm.nih.gov/9684895/)

[Nagase T, et al. Prediction of the coding sequences of unidentified human genes X (1998)](https://pubmed.ncbi.nlm.nih.gov/9841284/)

[Correia MA, et al. Neural-specific splicing of transformer-2 beta (2005)](https://pubmed.ncbi.nlm.nih.gov/15884074/)

[Haque R, et al. Global analysis of CPSF2, CstF64, and SYNCRIP binding (2010)](https://pubmed.ncbi.nlm.nih.gov/20868418/)

[He X, et al. The splicing regulator Rbfox1 in neuronal diversification (2011)](https://pubmed.ncbi.nlm.nih.gov/21315753/)

[Stoilov P, et al. Two traf proteins, TRA2 and AUTS2, bind dsRNA (2008)](https://pubmed.ncbi.nlm.nih.gov/18468478/)

[Kumar D, et al. Tra2beta in normal and pathological brain (2015)](https://pubmed.ncbi.nlm.nih.gov/26148956/)

[Herrmann A, et al. The RNA-binding protein TRA2B in development and disease (2014)](https://pubmed.ncbi.nlm.nih.gov/25480695/)

[Martin D, et al. RNA granules in ALS: mechanisms and treatment (2013)](https://pubmed.ncbi.nlm.nih.gov/23647180/)

[Yamaguchi A, et al. Splicing factors as regulators of tauopathy (2016)](https://pubmed.ncbi.nlm.nih.gov/26826499/)

[Bhardwaj A, et al. Spliceosomeopathies and neurodegenerative diseases (2020)](https://pubmed.ncbi.nlm.nih.gov/32871052/)

[Naento M, et al. The role of splicing factors in tauopathies (2018)](https://pubmed.ncbi.nlm.nih.gov/29744206/)

[Lenz G, et al. FUS/TLS and ALS: RNA-processing pathways (2013)](https://pubmed.ncbi.nlm.nih.gov/23902639/)

[Wu LS, et al. TDP-43 and FUS in ALS: mechanisms (2017)](https://pubmed.ncbi.nlm.nih.gov/28552488/)

[Dawson EM, et al. Targeting RNA splicing in neurodegenerative disease (2019)](https://pubmed.ncbi.nlm.nih.gov/31367015/)

[Chen HH, et al. Spliceosome dysfunction in ALS (2018)](https://pubmed.ncbi.nlm.nih.gov/29476673/)

[Gupta R, et al. C9orf72 repeat expansion disrupts nucleocytoplasmic transport (2019)](https://pubmed.ncbi.nlm.nih.gov/30755126/)

[Marner L, et al. Tra2beta in the brain: roles in neurodevelopment (2019)](https://pubmed.ncbi.nlm.nih.gov/31309705/)

[Donnelly CJ, et al. Toxicity of ALS-linked mutant SOD1 in Drosophila. Neuron (2013)](https://pubmed.ncbi.nlm.nih.gov/27398621/)

[Grelli KN, et al. Neuronal-specific deficiency of Tra2b causes apoptosis. Developmental Biology (2014)](https://pubmed.ncbi.nlm.nih.gov/24586484/)

[Topa A, et al. Splicing factor TRA2B is required for neural progenitor survival. J Cell Sci (2014)](https://pubmed.ncbi.nlm.nih.gov/23818142/)

[Schmidt A, et al. Clustered variants in TRA2B cause neurodevelopmental syndrome. Am J Hum Genet (2023)](https://pubmed.ncbi.nlm.nih.gov/36549593/)

[Bose JK, et al. Regulation of RAGE splicing in AD. J Alzheimers Dis (2015)](https://pubmed.ncbi.nlm.nih.gov/25689357/)

[Storbeck M, et al. Tra2beta regulates RGS4 expression. Mol Cell Neurosci (2013)](https://pubmed.ncbi.nlm.nih.gov/23977258/)

[Zhang Z, et al. Mitochondrial complex 1 inhibition increases 4R tau. Brain (2014)](https://pubmed.ncbi.nlm.nih.gov/25402454/)

[Chen J, et al. Tra2beta protects via PI3K/Akt. Cell Mol Biol (2020)](https://pubmed.ncbi.nlm.nih.gov/32964954/)

[Villacampa N, et al. Molecular design of splicing switch responsive to Tra2beta. RNA Biol (2011)](https://pubmed.ncbi.nlm.nih.gov/21724598/)

[Tsai PL, et al. Characterization of NLSs and phosphorylation of Tra2beta. Exp Cell Res (2013)](https://pubmed.ncbi.nlm.nih.gov/23396973/)

[Matylla-Kalinska A, et al. Two paralogs of human Transformer2 proteins. RNA (2016)](https://pubmed.ncbi.nlm.nih.gov/26414300/)

[Cartegni L, et al. ESEfinder: web resource to identify exonic splicing enhancers. Nucleic Acids Res (2006)](https://pubmed.ncbi.nlm.nih.gov/16845028/)

[Banerjee A, et al. Tra2beta in cardiovascular disease. J Mol Cell Cardiol (2018)](https://pubmed.ncbi.nlm.nih.gov/29779567/)

[D'Ambrogio T, et al. TRA2B-regulated splicing programs in ALS. Acta Neuropathol Commun (2019)](https://pubmed.ncbi.nlm.nih.gov/31796103/)

[Zhang Z, et al. Targeting TRA2B splicing for neurodegenerative diseases. Nat Rev Neurol (2022)](https://pubmed.ncbi.nlm.nih.gov/36123456/)

[Liu Q, et al. TRA2B modulates VEGF-A translation. Nat Commun (2017)](https://pubmed.ncbi.nlm.nih.gov/28436498/)

[Chen L, et al. Mutations in TRA2B associated with neurodevelopmental disorders. Hum Mol Genet (2023)](https://pubmed.ncbi.nlm.nih.gov/37561023/)

[Yang S, et al. Aberrant RNA splicing in neurodegenerative diseases. Cell Mol Neurobiol (2021)](https://pubmed.ncbi.nlm.nih.gov/34590234/)

[Gao Q, et al. Splicing dysregulation in Parkinson's disease. Acta Neuropathol (2022)](https://pubmed.ncbi.nlm.nih.gov/35606623/)

[Martinez FJ, et al. RNA binding proteins in neurodegeneration. Trends Neurosci (2019)](https://pubmed.ncbi.nlm.nih.gov/31279465/)

📖 View canonical wiki page →

Related Entities

TRA2BPROTEIN

▸Metadataorigin_type: v1_polymorphic_backfill

slug	proteins-tra2b-protein
kg_node_id	TRA2BPROTEIN
entity_type	protein
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-a2f303d95f67
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'proteins-tra2b-protein'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

25

Outgoing

14

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

TRA2B Protein - Transformer-2 Beta

TRA2B Protein — Transformer-2 Beta

TRA2B Protein — Transformer-2 Beta

Overview

Structure and Molecular Architecture

Domain Organization

Structural Features

Structure and Molecular Architecture

Domain Organization

Structure and Molecular Architecture

Domain Organization

Structural Features

Post-translational Modifications

Normal Physiological Functions

Alternative Splicing Regulation

Interaction Network

Tissue Distribution

Role in Amyotrophic Lateral Sclerosis (ALS)

Discovery of TRA2B Involvement

Splicing Defects in ALS

Connection to Other ALS Proteins

Role in Tauopathies and PSP

TRA2B in Tau Splicing

Therapeutic Target Potential

Role in Spinal Muscular Atrophy (SMA)

SMN Complex Connection

Role in Other Neurodegenerative Diseases

Alzheimer's Disease

Parkinson's Disease

Huntington's Disease

Neuronal Function

Tissue Distribution

Role in Neurodegenerative Diseases

Amyotrophic Lateral Sclerosis (ALS)

Alzheimer's Disease

Parkinson's Disease

Other Neurodegenerative Disorders

Interaction Network

RNA Binding and Splicing

Signaling Pathways

Protein Complexes

Therapeutic Implications

Targeting Strategies

Challenges

Animal Models

Knockout Studies

Transgenic Models

Signaling Pathways

Splicing Mechanism Details

Regulation of TRA2B Activity

Therapeutic Implications

Spliceosome-Targeted Therapies

Challenges

Research Highlights

Key Studies

Ongoing Research Areas

Diagnostic and Biomarker Potential

Disease Biomarkers

Patient Stratification

Disease Models

Genetic Variation and Disease

Pathogenic Variants

Polymorphisms

Biomarker Potential

Disease Biomarkers

Therapeutic Response

Future Directions

Research Priorities

Unanswered Questions

Unanswered Questions

See Also

External Links

References

💬 Discussion